Travere Therapeutics said Tuesday it plans to ask the FDA for approval of its kidney drug Filspari in a rare condition known as focal segmental glomerulosclerosis, or FSGS, using a secondary endpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback